Dr. Jonathan Barratt on Sibeprenlimab for IgAN
#KidneyWk #nephrology #iganephropathy #kidneydisease Jonathan Barratt, PhD, is a professor and lead of the renal research group at the University of Leicester. He is lead author of "The Anti-APRIL Antibody Sibeprenlimab Reduced Circulating Immune Complexes in Patients With IgA Nephropathy in the Phase 2 ENVISION Randomized Controlled Trial,” which was presented at ASN Kidney Week 2024. Joel Topf, MD, spoke with Dr. Barratt at Kidney Week about the findings on this anti-APRIL IgAN treatment.
▶︎
Targeted Disease Modification in IgA Nephropathy
▶︎
The Pathogenesis of IgA Nephropathy and Future Treatment Options. ft Dana Rizk, MD
▶︎
2025 update on what's happening in IgA Nephropathy
▶︎
#15 IgA nephropathy, with Jonathan Barratt
▶︎
Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide
▶︎
The IgAN Treatment Pipeline: B-cell Pathway
![Packaging solutions Video Mix General - 2018 Edition [by Imanpack 1314]](https://i.ytimg.com/vi/cvbM94_h0hQ/hqdefault.jpg?sqp=-oaymwEjCNACELwBSFryq4qpAxUIARUAAAAAGAElAADIQj0AgKJDeAE=&rs=AOn4CLAnQZjD_9AfEIgvHWUbYsRBmef8dw)
▶︎
Packaging solutions Video Mix General - 2018 Edition [by Imanpack 1314]
▶︎
Updates in IgA Nephropathy - Part 1 with Dr. Brad Rovin
▶︎
Updates to the KDIGO Guidelines for the treatment of IgA nephropathy, with Prof Jonathan Barratt
▶︎
Felzartamab Enters Phase 3 Trial for PMN
▶︎
IgA Nephropathy Basics (including an update on new treatments).
▶︎
I Lived Another Life In a Coma | It Happened to Me
▶︎
Worst Plane Landing Fails Caught on Camera
▶︎
Billionaire's WARNING: I'm SELLING. The Crash Is Already Here!
▶︎
Updates in IgA Nephropathy - Part 2 with Dr. Jürgen Floege
▶︎
Evolving Treatment Paradigms in IgA NephropathyAn Overview of the Sibeprenlimab Phase 3 VISIONARY T
▶︎
TARPEYO Reduces the Loss of Kidney Function in IgA Nephropathy
▶︎
Understanding Atrasentan (Vanrafia) for IgA Nephropathy, with Richard Lafayette, MD
▶︎
IgA Nephropathy Clinical Trial: VISIONARY Trial (Sibeprenlimab)
▶︎